Dr. Reddy's Counts On U.S. Market For This Fiscal Year
This article was originally published in PharmAsia News
India's Dr. Reddy's Laboratories plans to launch as many as 12 generic drugs in the United States during the current fiscal year, relying on the nation to be the firm's main growth source
You may also be interested in...
Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.
Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.